Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

Christopher R. Grant; Elaine J. Chiao; Zhaohui L. Arter; Cary Johnson; Truc Tran; Farshid Dayyani; Krishnasu Tewari; Valery Vilchez; Joseph Carmichael; May Cho

doi:10.12659/AJCR.939448

29 June 2023 : Case report USA

Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology

Christopher R. Grant^1ABCDEF*, Elaine J. Chiao^1EF, Zhaohui L. Arter^2ADE, Cary Johnson^3C, Truc Tran^3BE, Farshid Dayyani^2E, Krishnasu Tewari^2E, Valery Vilchez^4E, Joseph Carmichael

^4E, May Cho^2ABCDE

DOI: 10.12659/AJCR.939448

Am J Case Rep 2023; 24:e939448

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 1. (A) Abdomen demonstrating 18.03×49.58 mm ill-defined retroperitoneal mass with invasion of the posterior third portion of the duodenum before the initiation of Pembrolizumab. (B) CT abdomen shows interval decrease ill-defined retroperitoneal mass size from 18.03×49.58 mm to 7.2×21.2 after 6 months of treatment with pembrolizumab.

Back to the Article

Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

Your Privacy